Description
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 6
Primary Industries
- Drugs
- Cancer
- Disease
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 257477
Licensor grants
— an exclusive right and license under the Licensors Licensed Technology and rights to the Joint Technology, to research, have researched, develop, have developed, make, have made, use, offer for sale, sell, have sold, import and export the Licensed Compound and the Licensed Product in the Field outside the Licensor Territory; provided that Licensor reserves the right to conduct Development activities outside the Licensor Territory solely to support the Development and Commercialization of Licensed Compound and Licensed Products inside the Licensor Territory, and manufacture Licensed Compound and Licensed Products outside the Licensor Territory solely for use and distribution within the Licensor Territory; and,
— a non-exclusive right and license in the Field in the Licensor Territory under the Licensor Licensed Technology and rights to the Joint Technology, to the extent necessary for SubLicensee to perform its obligations under the Development Plan, and to Develop and manufacture the Licensed Compound and the Licensed Product in the Licensor Territory solely in support of Development and Commercialization of the Licensed Compound and the Licensed Product outside the Licensor Territory.
Previously, the development and commercialization rights to MM-398 in Europe and Asia had been licensed to Licensor. Sublicensee held the rights to the product in North America and all other territories around the world. Through this agreement, the worldwide rights to MM-398 have been reunited, with SubLicensee now having the right to develop and commercialize MM-398 in all territories of the world with the exception of Taiwan, where Licensor will retain its rights to develop and commercialize MM398.
The property of the original agreement which is being reassigned with this agreement is
Intellectual property relating to liposomal irinotecan; Product shall mean any pharmaceutical composition comprising liposomally encapsulated Irinotecan (( + )-(S)-4, 11-Diethyl-4, 12-dihydro-4-hydroxy-3, 14-dioxo-1 Hpyrano[3, 46,7)indolizino[L2-b]chinolin-9-yl[l,4 -bipiperidin el-1- carboxylate, CAS 97682-44-5). including salts thereof; and, patents for Liposomes Useful for Drug Delivery.
IPSCIO Record ID: 257475
The FDA has approved MM-398 (irinotecan liposome injection; Onivyde) in combination with 5-fluorouracil (5-FU) and leucovorin as a treatment for patients with metastatic pancreatic cancer following prior administration of a gemcitabine-based regimen.
IPSCIO Record ID: 257617
With the original agreement, Licensors intellectual property, Licensor grants the Licensee of China an exclusive right and license under Licensors Intellectual Property applicable to the Licensed Product to develop, manufacture, market, sell, use, offer for sale and import the Licensed Product in the Territory during the term of this Agreement.
Licensor grants the right of access, the right of reference and the right to use and incorporate all information provided to Licensee pursuant to obtaining the regulatory approval of the Licensed Product within the Territory and in performing the development, commercialization and all Licensees obligations in respect of the Licensed Product under this Agreement.
Product shall mean any pharmaceutical composition comprising liposomally encapsulated Irinotecan (( + )-(S)-4, 11-Diethyl-4, 12-dihydro-4-hydroxy-3, 14-dioxo-1 Hpyrano[3, 46,7)indolizino[L2-b]chinolin-9-yl[l,4 -bipiperidin el-1- carboxylate, CAS 97682-44-5). including salts thereof.
The patents are for Liposomes Useful for Drug Delivery.
MM-398 is a novel, stable nanotherapeutic encapsulation of the marketed chemotherapy drug irinotecan. MM-398 recently achieved its primary efficacy endpoints in Phase 2 clinical trials in pancreatic and gastric cancer.
IPSCIO Record ID: 257586
Licensor of Bermuda and its Parent, the Licensee, desire to amend the Agreement to transfer back to Licensor the right to develop and commercialize the Licensed Product in certain countries in Asia. The original agreement was exclusive.
Product shall mean any pharmaceutical composition comprising liposomally encapsulated Irinotecan (( + )-(S)-4, 11-Diethyl-4, 12-dihydro-4-hydroxy-3, 14-dioxo-1 Hpyrano[3, 46,7)indolizino[L2-b]chinolin-9-yl[l,4 -bipiperidin el-1- carboxylate, CAS 97682-44-5). including salts thereof.
The patents are for Liposomes Useful for Drug Delivery.
IPSCIO Record ID: 257476
Licensor grants the right of access, the right of reference and the right to use and incorporate all information provided to Licensee pursuant to obtaining the regulatory approval of the Licensed Product within the Territory and in performing the development, commercialization and all Licensees obligations in respect of the Licensed Product under this Agreement.
Product shall mean any pharmaceutical composition comprising liposomally encapsulated Irinotecan (( + )-(S)-4, 11-Diethyl-4, 12-dihydro-4-hydroxy-3, 14-dioxo-1 Hpyrano[3, 46,7)indolizino[L2-b]chinolin-9-yl[l,4 -bipiperidin el-1- carboxylate, CAS 97682-44-5). including salts thereof.
The patents are for Liposomes Useful for Drug Delivery.
Irinotecan is a cancer medicine that interferes with the growth and spread of cancer cells in the body. Irinotecan is used to treat cancers of the colon and rectum. It is usually given with other cancer medicines in a combination chemotherapy.
IPSCIO Record ID: 372449
Licensed Patent Rights means all Patent Rights in the Licensed Territory Controlled by Licensor that claim inventions necessary or useful for the development, manufacture or Commercialization of any Licensed Product in the Licensed Territory, including Licensor’s rights to any Joint Patent Rights.
MM-398, also known as nal-IRI, is a nanoliposomal formulation of irinotecan encapsulated in a lipid sphere. In tumor cell models, this nanoliposomal technology was found to alter the pharmacokinetic properties of irinotecan, increasing the retention time and exposure to SN-38—the active form of the drug. SN-38 functions by inhibiting topoisomerase I (an essential enzyme involved in DNA transcription and replication) and promoting cell death.
The collaboration agreement is to develop and market Licensor’s pancreatic cancer drug outside the United States.
